Watching Ocuphire Pharma; Note From Canaccord Says 'FDA Approved Ocuphire's Ryzumvi For Reversal Of Mydriasis Ahead Of Schedule (PDUFA Date 09/28). The first $10M Milestone Payment Is Expected From Partner Viatris'
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Ocuphire Pharma's Ryzumvi for reversal of mydriasis ahead of schedule. The first $10M milestone payment is expected from partner Viatris.
September 26, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Viatris is expected to make the first $10M milestone payment to Ocuphire Pharma following the FDA approval of Ryzumvi.
Viatris is expected to make a significant payment to Ocuphire Pharma following the FDA approval of Ryzumvi. This could potentially have a negative impact on Viatris' short-term financial position and therefore its stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
Ocuphire Pharma's Ryzumvi has been approved by the FDA ahead of schedule, which could lead to increased revenues from the product.
The FDA approval of Ryzumvi ahead of schedule is a positive development for Ocuphire Pharma. This could lead to increased revenues from the product, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100